Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

Filgrastim 3belinostat 2Gemcitabine 2Docetaxel 2Carboplatin 2toripalimab 1etoposide phosphate 1durvalumab 1capivasertib 1Topotecan 1Thiotepa 1Thalidomide 1Taxes 1Quality of Life 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Medicare Part B 1Immunotherapy 1Immunoglobulin G 1Ifosfamide 1Fluorouracil 1Fentanyl 1Etoposide 1Drug Therapy 1Disulfides 1Cyclophosphamide 1Cryosurgery 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × Medicare Part B × Head & Neck × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡